Non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for ...

Non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute ... known as ...

Among patients with curatively resected early-stage biliary tract cancer (BTC), recent study findings from a real-world cohort trial revealed the value of circulating tumor DNA (ctDNA) as a prognostic ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma This retrospective analysis included patients with cancer who had commercial ctDNA tests (K-Track, Gene ...

At ctDNA levels below 10 mutant copies/mL (0.25% VAF) it can reassure patients that progression is unlikely, while levels above 100 copies/mL (2.5% VAF) are associated with at least a 90% chance ...

In conclusion, ctDNA methylation in both tissue and plasma can effectively differentiate malignancy from benign disease and holds great potential as a biomarker for early lung cancer diagnosis.

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in ...

Greatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with a confirmed objective response rate (cORR ...

(1) Interest expense includes net gains recorded of $10.3 million for each of the twelve months ended December 31, 2024 and 2023, from the settlement of convertible notes. The gains represent the ...